{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,2]],"date-time":"2023-04-02T16:21:14Z","timestamp":1680452474335},"reference-count":55,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1684\/bdc.2011.1390","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T20:01:59Z","timestamp":1565726519000},"page":"761-767","source":"Crossref","is-referenced-by-count":1,"title":["AP24534 (Ponatinib) : le prochain traitement de la leuc\u00e9mie aigu\u00eb lymphoblastique \u00e0 chromosome Philadelphie ?"],"prefix":"10.1016","volume":"98","author":[{"given":"Xavier","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2011.1390_bib0005","first-page":"833","article-title":"Strat\u00e9gies th\u00e9rapeutiques actuelles dans les leuc\u00e9mies aigu\u00ebs lymphoblastiques de l\u2019adulte","volume":"90","author":"Thomas","year":"2003","journal-title":"Bull Cancer"},{"key":"10.1684\/bdc.2011.1390_bib0010","first-page":"713","article-title":"Leuc\u00e9mie aigu\u00eb lymphoblastique du sujet \u00e2g\u00e9 : pronostic et traitement","volume":"91","author":"Thomas","year":"2004","journal-title":"Bull Cancer"},{"key":"10.1684\/bdc.2011.1390_bib0015","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1080\/10428190801993504","article-title":"Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia","volume":"49","author":"Thomas","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1684\/bdc.2011.1390_bib0020","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/0002-9343(94)90049-3","article-title":"Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients","volume":"97","author":"Preti","year":"1994","journal-title":"Am J Med"},{"key":"10.1684\/bdc.2011.1390_bib0025","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1182\/blood-2003-04-1299","article-title":"A report of the LALA-94 and LALA-SA groups on hypodiploidy with 30 to 39 chromosomes and near-triploidy: 2 possible expressions of a sole entity conferring poor prognosis in adult acute lymphoblastic leukemia (ALL)","volume":"104","author":"Charrin","year":"2004","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1390_bib0030","first-page":"196","article-title":"Philadelphia positive acute lymphoblastic leukemia in adults: age distribution. BCR breakpoint and prognostic significance","volume":"5","author":"Secker-Walker","year":"1991","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2011.1390_bib0035","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1046\/j.1365-2141.1996.d01-1968.x","article-title":"Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia","volume":"95","author":"Rieder","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1684\/bdc.2011.1390_bib0040","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/0092-8674(84)90438-0","article-title":"An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity","volume":"37","author":"Konopka","year":"1984","journal-title":"Cell"},{"key":"10.1684\/bdc.2011.1390_bib0045","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"10.1684\/bdc.2011.1390_bib0050","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","article-title":"The P190, P210, and P230 forms in the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity","volume":"189","author":"Li","year":"1999","journal-title":"J Exp Med"},{"key":"10.1684\/bdc.2011.1390_bib0055","first-page":"377","article-title":"The role of BCR\/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial","volume":"91","author":"Cimino","year":"2006","journal-title":"Haematologica"},{"key":"10.1684\/bdc.2011.1390_bib0060","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1684\/bdc.2011.1390_bib0065","first-page":"4236","article-title":"Crystal structure of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2011.1390_bib0070","first-page":"1661","article-title":"Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing M, 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)","volume":"4","author":"Beran","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2011.1390_bib0075","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1390_bib0080","doi-asserted-by":"crossref","first-page":"748a","DOI":"10.1182\/blood.V104.11.2738.2738","article-title":"Update of the hyper-CVAD and imatinib mesylate regimen in Philadelphia (Ph) positive acute lymphocytic leukemia","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1390_bib0085","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2006-03-011908","article-title":"Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia \u2013 results of the GRAAPH-2003 study","volume":"109","author":"De Labarthe","year":"2007","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1390_bib0090","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2005-11-4386","article-title":"Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"108","author":"Wassmann","year":"2006","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1390_bib0095","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1182\/blood-2004-04-1389","article-title":"Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia","volume":"104","author":"Towatari","year":"2004","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1390_bib0100","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","article-title":"High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group","volume":"24","author":"Yanada","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1390_bib0105","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood-2004-09-3785","article-title":"The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"105","author":"Lee","year":"2005","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1390_bib0110","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nrd1579","article-title":"Strategies to overcome resistance to targeted protein kinase inhibitors","volume":"3","author":"Daub","year":"2004","journal-title":"Nature Rev Drug Discov"},{"key":"10.1684\/bdc.2011.1390_bib0115","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance","volume":"99","author":"Branford","year":"2002","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1390_bib0120","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of philadelphia-positive patients. GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2011.1390_bib0125","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1684\/bdc.2011.1390_bib0130","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1390_bib0135","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/jnci\/92.20.1641","article-title":"Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571","volume":"92","author":"Gambacorti-Passerini","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1684\/bdc.2011.1390_bib0140","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.leu.2403257","article-title":"P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate","volume":"18","author":"Illmer","year":"2004","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2011.1390_bib0145","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-04-2601","article-title":"AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia","volume":"11","author":"Golemovic","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2011.1390_bib0150","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1684\/bdc.2011.1390_bib0155","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"10.1684\/bdc.2011.1390_bib0160","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2009-12-261586","article-title":"First report of phase 2 study of dasatinib with hyperCVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1390_bib0165","doi-asserted-by":"crossref","first-page":"10a","DOI":"10.1182\/blood.V110.11.7.7","article-title":"Dasatinib as front-line monotherapy for the induction treatment of adult and elderly Ph+ acute lymphoblastic leukemia (ALL) patients: interim analysis of the GIMEMA prospective study LAL1205","volume":"110","author":"Foa","year":"2007","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1390_bib0170","first-page":"828a","article-title":"Nilotinib in patients (pts) with relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib","volume":"110","author":"Ottmann","year":"2007","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1390_bib0175","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2141.2009.07666.x","article-title":"Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"145","author":"Gruber","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1684\/bdc.2011.1390_bib0180","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2174\/156802608784911635","article-title":"Inhibitors of ABL and the ABL-T315I mutation","volume":"8","author":"Noronha","year":"2008","journal-title":"Curr Top Med Chem"},{"key":"10.1684\/bdc.2011.1390_bib0185","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2011.1390_bib0190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11523-008-0100-y","article-title":"Treatment selection after imatinib resistance in chronic myeloid leukemia","volume":"4","author":"Jabbour","year":"2009","journal-title":"Targ Oncol"},{"key":"10.1684\/bdc.2011.1390_bib0195","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/blood-2007-06-096396","article-title":"In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib","volume":"111","author":"Khorashad","year":"2008","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1390_bib0200","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-08-0117","article-title":"Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia","volume":"14","author":"Quintas-Cardama","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2011.1390_bib0205","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1747-0285.2007.00556.x","article-title":"Crystal structure of the T315I mutant of Abl kinase","volume":"70","author":"Zhou","year":"2007","journal-title":"Chem Biol Drug Des"},{"key":"10.1684\/bdc.2011.1390_bib0210","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tobarski","year":"2006","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2011.1390_bib0215","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of wild-type and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1684\/bdc.2011.1390_bib0220","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1182\/blood-2009-04-219410","article-title":"Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation","volume":"114","author":"Nicolini","year":"2009","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1390_bib0225","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood-2006-11-052373","article-title":"Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"110","author":"Pfeifer","year":"2007","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1390_bib0230","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1390_bib0235","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1390_bib0240","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1002\/cncr.24601","article-title":"Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009","volume":"115","author":"Quintas-Cardama","year":"2009","journal-title":"Cancer"},{"key":"10.1684\/bdc.2011.1390_bib0245","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","volume":"53","author":"Huang","year":"2010","journal-title":"J Med Chem"},{"key":"10.1684\/bdc.2011.1390_bib0250","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1684\/bdc.2011.1390_bib0255","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O\u2019Hare","year":"2007","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1390_bib0260","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myeloid leukaemia following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1390_bib0265","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib, dasatinib (BMS-354825), and nilotinib (AMN107) in an n-ethyl-n-nitrourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1390_bib0270","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/blood.V114.22.643.643","article-title":"A phase 1 trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutations","volume":"114","author":"Cortes","year":"2009","journal-title":"Blood"},{"key":"10.1684\/bdc.2011.1390_bib0275","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1200\/jco.2010.28.15_suppl.6511","article-title":"Phase 1 trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and hematologic malignancies","volume":"28","author":"Talpaz","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745511530610X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745511530610X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T08:39:54Z","timestamp":1602491994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745511530610X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S000745511530610X"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2011.1390","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}